Ion Beam Applications SA (EBR:IBAB)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 397.65M |
| Revenue (ttm) | 620.20M |
| Net Income (ttm) | 12.70M |
| Shares Out | 29.20M |
| EPS (ttm) | 0.43 |
| PE Ratio | 31.67 |
| Forward PE | 11.02 |
| Dividend | 0.25 (1.84%) |
| Ex-Dividend Date | Jun 18, 2025 |
| Volume | 23,193 |
| Average Volume | 43,398 |
| Open | 13.60 |
| Previous Close | 13.62 |
| Day's Range | 13.44 - 13.60 |
| 52-Week Range | 9.90 - 15.90 |
| Beta | 1.22 |
| RSI | 46.17 |
| Earnings Date | Apr 30, 2026 |
About Ion Beam Applications
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally. It operates through Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production o... [Read more]
Financial Performance
In 2025, Ion Beam Applications's revenue was 620.20 million, an increase of 24.50% compared to the previous year's 498.16 million. Earnings were 12.70 million, an increase of 37.25%.
Financial StatementsNews
IBA Business Update – Third Quarter 2023
Louvain-La-Neuve, Belgium, 16 November 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter...
IBA Reports Half Year 2022 Results
RECORD ORDER INTAKE AND BACKLOG ACROSS THE GROUP